Intuitive Surgical Stock Falls Despite da Vinci 5 Placements Jump
Intuitive Surgical (ISRG) reported Q3 non-GAAP EPS of $3.00, beating estimates, on revenue of $3.05B, also exceeding expectations. GAAP EPS fell due to a $450M litigation charge. Shares dropped 7.76% premarket. Revenue rose 22%, driven by procedure growth and higher lease revenue. Da Vinci system placements increased to 546 from 427 a year earlier, with 315 being the new da Vinci 5 model.
How this was made
The 30-second read
Why it matters
Earnings beat on non‑GAAP metrics was outweighed by GAAP EPS decline and a large settlement, driving a 7.8% pre‑market drop despite a $2.94B buyback.
Market read
The mixed earnings signal creates short‑term downside risk for ISRG while highlighting strong underlying growth trends.
What to watch
Tariff impact on margins and continued demand for da Vinci 5 systems may underpin longer‑term upside.
Background
Intuitive Surgical reported Q3 2026 results, highlighting a 22% revenue increase, procedural growth, and a $450M antitrust settlement charge.
Ticker impact
Q3 earnings beat on non‑GAAP EPS and revenue, but shares fell 7.8% pre‑market after a $450M antitrust settlement charge and a large buyback.
likely further downside as investors price in the settlement hit and profit‑taking after the buyback.
Despite strong top‑line growth and a $2.94B share repurchase, the market reacted negatively to the GAAP EPS decline and litigation charge, indicating bearish short‑term sentiment.
Market effects
Robotic surgery peers may see modest pull‑back as investors reassess litigation risk.
U.S. healthcare equipment sector could face slight pressure.
Limited; impact confined to medical‑device space.
Counterpoint
The strong procedural growth and massive buyback could support a rebound if the settlement charge is viewed as a one‑off.
Key entities
- companyIntuitive Surgical
Medical‑device maker of da Vinci surgical systems.
